June 6, 2025
Source: drugdu
98
On the evening of June 4, Wantai BioThe company announced that the nine-valent human papillomavirus (HPV) vaccine (Escherichia coli) (trade name: Xinkening 9) jointly developed by the company's wholly-owned subsidiary Xiamen Wantai Canghai Biotechnology Co., Ltd. ("Wantai Vaccine") and Xiamen University has been approved for marketing by the National Medical Products Administration. Previously, there was only one nine-valent HPV vaccine on the market worldwide, which was developed by MerckGardasil® 9.
Wantai Vaccine, located in Xiamen Biomedicine Port, has worked closely with the National Infectious Disease Diagnostic Reagent and Vaccine Engineering Technology Research Center (NIDVD) of Xiamen University to build a mature industry-university-research model. The two parties have developed and launched a number of innovative vaccines, from hepatitis E vaccine, bivalent HPV vaccine, to the current nine-valent HPV vaccine (Xinkening 9). The launch of Xinkening 9 is the result of 18 years of collaborative innovation in "industry-university-research" between the two parties.
Wantai Bio said that the approval of the marketing license application for the nine-valent HPV vaccine will be conducive to the promotion and use of the company's HPV vaccine, enrich the company's product line, further enhance the company's core competitiveness, and lay a solid foundation for the company's continued stable development.
https://finance.eastmoney.com/a/202506043421922175.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.